Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients.

Front Microbiol

Aix Marseille Université, Institut de Recherche pour le Développement, Microbes Evolution Phylogeny and Infections (MEPHI), Assistance Publique Hôpitaux de Marseille, Marseille, France.

Published: March 2023

AI Article Synopsis

  • Kidney transplant recipients (KTRs) remain at high risk for severe COVID-19, necessitating booster vaccinations and monoclonal antibody treatments for better protection.
  • A study found that only 46% of vaccinated KTRs could neutralize various SARS-CoV-2 variants, with many showing poor response to Omicron variants.
  • Tixagevimab/cilgavimab showed limited effectiveness, especially against newer Omicron strains, highlighting the need for improved strategies for protecting KTRs from COVID-19.

Article Abstract

Introduction: Kidney transplant recipients (KTRs) are at high risk of severe COVID-19, even when they are fully vaccinated. Additional booster vaccinations or passive immunization with prophylactic monoclonal antibodies are recommended to increase their protection against severe COVID-19.

Methods: Here, we describe the neutralization of SARS-CoV-2 Delta, Omicron BA.1, BA.2, BA.4, and BA.5 variants, firstly by 39 serum samples from vaccinated KTRs exhibiting anti-spike antibody concentrations ≥264 binding antibody units (BAU)/mL and, secondly, by tixagevimab/cilgavimab.

Results: No neutralization was observed for 18% of the KTRs, while serum from only 46% of patients could neutralize the five variants. Cross-neutralization of the Delta and Omicron variants occurred for 65-87% of sera samples. The anti-spike antibody concentration correlated with neutralization activity for all the variants. The neutralization titers against the Delta variant were higher in vaccinated KTRs who had previously presented with COVID-19, compared to those KTRs who had only been vaccinated. Breakthrough infections occurred in 39% of the KTRs after the study. Tixagevimab/cilgavimab poorly neutralizes Omicron variants, particularly BA.5, and does not neutralize BQ.1, which is currently the most prevalent strain.

Discussion: As a result, sera from seropositive vaccinated KTRs had poor neutralization of the successive Omicron variants. Several Omicron variants are able to escape tixagevimab/cilgavimab.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095161PMC
http://dx.doi.org/10.3389/fmicb.2023.1147455DOI Listing

Publication Analysis

Top Keywords

omicron variants
20
vaccinated ktrs
12
successive omicron
8
variants
8
monoclonal antibodies
8
kidney transplant
8
transplant recipients
8
delta omicron
8
anti-spike antibody
8
ktrs
7

Similar Publications

Phenotypic Classification of Multisystem Inflammatory Syndrome in Children Using Latent Class Analysis.

JAMA Netw Open

January 2025

Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Importance: Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but severe hyperinflammatory illness that occurs 2 to 6 weeks after SARS-CoV-2 infection. Presentation overlaps with other conditions, and risk factors for severity differ by patient. Characterizing patterns of MIS-C presentation can guide efforts to reduce misclassification, categorize phenotypes, and identify patients at risk for severe outcomes.

View Article and Find Full Text PDF

Clinical Characteristics During and After COVID-19 Infection Among Healthcare Workers During the First Wave of Omicron in Chongqing, China.

Immun Inflamm Dis

January 2025

Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Background: Revealing the clinical manifestations and associations of COVID-19 before and after negative transition remains an area of significant uncertainty. The aim of this study is to investigate the clinical characteristics observed during and after Omicron infection among a specific population, namely healthcare workers (HCWs).

Methods: From November 4, 2022, to January 15, 2023, HCWs in our hospital were enrolled to document clinical symptoms, prevention, and treatment for COVID-19 using a structured questionnaire.

View Article and Find Full Text PDF

Impact of SARS-CoV-2 variants on viral infectivity and the role of the renin-angiotensin-aldosterone system.

Hypertens Res

January 2025

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Balance between Protective vs. Exacerbating Effects of ACEIs and ARBs in Omicron Variant Infections. The spike protein on the surface of the Omicron variant has a high affinity for ACE2, making it more prone to enter cells and induce ACE2 downregulation.

View Article and Find Full Text PDF

Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the need for an effective vaccine has appeared crucial for stimulating immune system responses to produce humoral/cellular immunity and activate immunological memory. It has been demonstrated that SARS-CoV-2 variants escape neutralizing immunity elicited by previous infection and/or vaccination, leading to new infection waves and cases of reinfection. The study aims to gain into cases of reinfections, particularly infections and/or vaccination-induced protection.

View Article and Find Full Text PDF

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.

Signal Transduct Target Ther

January 2025

Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.

The newly emerged variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) demonstrate resistance to present therapeutic antibodies as well as the capability to evade vaccination-elicited antibodies. JN.1 sublineages were demonstrated as one of the most immune-evasive variants, showing higher neutralization resistance compared to XBB.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!